Cancer Care Fund
What Is It?
The Cancer Care Fund is a one-time financial assistance scheme to alleviate the financial burden of newly-diagnosed cancer patients from low or middle income families within the first 6 months of diagnosis.
Since the inception of this fund from 2015, more than S$5.64 million in aid was disbursed, assisting more than 6,200 patients.
Who Can Apply?
- Singaporeans or Permanent Residents (there are exceptions for non-Resident applicants whose parents/spouse/children are Singaporeans or Permanent Residents, and reside in Singapore for a continuous period of not less than 5 years)
- Newly-diagnosed cancer patients within the first 6 months of the date of diagnosis
- Patients who meet the income requirements of the Blue/Orange Community Health Assist Scheme (CHAS)
Funding Assistance
Blue Health Assist card holders with a per capita monthly income of less than $1,200 will receive $1,000.
Orange Health Assist card holders with a per capital monthly income of less than $2,000 but more than $1,200 will receive $500.
Documents Required
- NRIC
- Application forms duly completed and signed
- CHAS card (Blue or Orange only) OR Public Assistance OR Special Grant Card
- Permanent Residents and non-residents without CHAS should complete the income declaration form
- Medical memo or certificate stating clearly the date of diagnosis (as and when appropriate)
- Applicant’s bank book or bank statement (for GIRO mode of payment)
How To Apply?
The necessary application forms may be found at the link. Please approach your doctor or medical social worker to complete and submit your application forms, and then send them to welfare@singaporecancersociety.org.sg. Alternatively, you may contact us for more information.
Welfare Aid Fund
What Is It?
The Welfare Aid fund provides temporary financial assistance and/or medical supplies to enhance the well-being of needy cancer patients. Medical supplies include the supply of milk, diapers, medical dressings, stoma bags and other medical equipment.
Welfare aid mitigates the financial strain endured by patients and their families, which may arise from unemployment, loss of income, and high treatment costs. Funding may be accessed through healthcare professionals or medical social workers from various hospitals, hospices, and voluntary welfare organisations in Singapore.
Since its inception in 2005, more than S$15.12 million in aid was disbursed assisting more than 6,400 patients.
Who Can Apply?
- Singaporeans or Permanent Residents (there are exceptions for non-Resident applicants whose parents/spouse/children are Singaporeans or Permanent Residents, and reside in Singapore for a continuous period of not less than 5 years)
- Patients with a per capita income of less than $1,200
- Patients and immediate household with limited household savings
- Patients who meet the means-test criteria administered by SCS
Funding Assistance
Funding amounts will vary according to the successful applicant's healthcare and financial needs.
Documents Required
- Copy of NRIC (front and back) of patient and immediate family members staying in the same household
- The most recent:
o bank statement or passbook entry; and
o payslip or income tax assessment form; and
o 15 months CPF transaction history statement; and
o Cash investment Statement (if applicable)
- Medical memo* or certificate
- Documents on assistance received from other organisations.
*Please informed that the memo for medical supplies will need to be completed by the respective medical professionals, as follows:
• Milk feed to be recommended by Dietitian
• Ostomy appliances to be recommended by Stoma Nurse
• Other medical supplies 9e.g. wound dressing, diapers, etc.) to be recommended by Doctor/Nurse
How To Apply?
Please approach your doctor or medical social worker to complete and submit your application forms, and then send them to welfare@singaporecancersociety.org.sg.. Alternatively, you may contact us for more information.
Cancer Treatment Fund
What Is It?
This fund provides financial assistance to needy cancer patients to subsidise part of their cancer treatment costs. Cancer patients are referred to the Society by their healthcare professionals or medical social workers from various restructured hospitals in Singapore.
Since the inception of this fund in 2005, more than S$18.70 million in aid was disbursed, assisting more than 5,500 patients.
Who Can Apply?
- Singaporeans or Permanent Residents (there are exceptions for non-Resident applicants whose parents/spouse/children are Singaporeans or Permanent Residents, and reside in Singapore for a continuous period of not less than 5 years)
- Patients must be subsidised in a restructured hospital
- Patients who meet the medical and means-test criteria administered by SCS
Funding Assistance
Successful applicants will receive subsidies for the approved drug(s) or treatment(s) of up to 100% or $6,000 per cycle/month, whichever is lower. The subsidy is limited to a maximum of $50,000 per person.
How To Apply?
The necessary application forms may be found at the link. Please approach your doctor or medical social worker to complete and submit your application forms, and then sned them to welfare@singaporecancersociety.org.sg. Alternatively, you may contact us for more information.
Documents Required
- Copy of NRIC (front and back) of patient and immediate family members staying in the same household
- The most recent:
- bank statement or passbook entry; and
- payslip or income tax assessment form; and
- 15 month CPF transaction history statement; and
- Cash investment Statement (if applicable)
- Patient referral form and medical report(s) (i.e. scan report(s), blood test report(s) and/or histopathology report(s)) provided by treating physician
- MediFund certificate (if applicable)
SCS Patient Access Programme
SCS has tied up with various pharmaceutical companies to help patients with treatment.
For more info email: welfare@singaporecancersociety.org.sg
- SCS–Takeda Partnership
Treatment drug and type of cancers and indications
Adcetris (Brentuximab) – Relapsed or Refractory CD30+ Hodgkin Lymphoma, Systematic Anaplastic Large Cell Lymphoma (sALACL) or CD30+ Cutaneous T-Cell Lymphoma (CTCL)
- SCS–Merck Partnership
Treatment drug and type of cancers and indications
Erbitux (Cetuximab) – EGFR-expressing, RAS wild-type Mets Colorectal Cancer, SCC of the Head and Neck
- SCS–MSD Partnership
The SCS–MSD Enhanced PAP on Keytruda (Pembrolizumab) 200mg per treatment cycles applies only after 1st tier funding on KeytrudaPAP at restructured hospitals
Treatment drug and type of cancers and indications
Keytruda (Pembrolizumab) - Treatment of patients with unresectable or metastatic melanoma; adjuvant treatment of patients with melanoma with lymph node involvement who have undergone complete resection; metastatic non-small cell lung carcinoma (NSCLC) PD-L1 ≥50% tumor proportion score (TPS) with no EGFR or ALK genomic tumor aberrations; metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations; locally advanced or metastatic NSCLC PD-L1 ≥1% TPS and who has received platinum-containing chemotherapy; first-line metastatic squamous NSCLC; first line metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 with a CPS ≥1; refractory classical Hodgkin Lymphoma (cHL); locally advanced or metastatic urothelial carcinoma (UC) PD-L1 ≥10% combined positive score (CPS) and who is not eligible for cisplatin-containing chemotherapy; locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy; first-line locally advanced or metastatic carcinoma of the esophagus or HER2 negative gastroesophageal junction (GEJ) adenocarcinoma (tumors with epicenter 1 to 5 centimeters above the GEJ) that is not amenable to surgical resection or definitive chemoradiation; first-line metastatic microsatellite instabilityhigh (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC); first-line advanced renal cell carcinoma (RCC); advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior chemotherapy in the metastatic setting and are not candidates for curative surgery or radiation; locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by a validated test and who have not received prior chemotherapy for metastatic disease.
- SCS – AstraZeneca Partnership (PAP@SGH Enrolment)
Treatment drug and type of cancers and indications
Calquence (acalabrutinib) – Mantle Cell Lymphoma (MCL) with at least one prior treatment, Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- SCS – Roche Partnership (ARiSE Patient Support Programme)
This programme is designed to provide support to ARISE patients who require additional financial assistance. In order to be eligible, Patients must be enrolled onto the Roche ARISE programme for the following products & indications:
Treatment drug and type of cancers and indications
Perjeta + Herceptin - HER2+ metastatic Breast Cancer (BC), HER2+ Early Breast Cancer (eBC) (neoadjuvant, adjuvant: high risk) Kadcyla - HER2+ metastatic BC, HER2+ eBC (adjuvant: residual disease) Tecentriq - PD-L1+ metastatic Triple-Negative Breast Cancer (TNBC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), 1L metastatic Non-Small Cell Lung Cancer (NSCLC) (PD-L1 expression ≥ 50% tumor cells (TC) or ≥ 10% tumor-infiltrating immune cells (IC), 1L metastatic non-squamous NSCLC, 2L metastatic NSCLC Tecentriq + Avastin - 1L non-squamous NSCLC, 1L unresectable Hepatocellular Carcinoma (HCC) Alecensa - 1L & 2L ALK+ advanced or metastatic NSCLC Gazyva - 1L follicular lymphoma, rituximab-refractory follicular lymphoma, 1L Chronic Lymphocytic Leukemia (CLL)
